Minerva Neurosciences (NERV) Profit After Tax (2013 - 2026)
Minerva Neurosciences (NERV) posted Profit After Tax of -$125.4 million for Q1 2026, up 55.79% on a QoQ basis from -$283.7 million in Q4 2025, and down 3241.47% year-over-year from $4.0 million in Q1 2025.
Minerva Neurosciences (NERV) Profit After Tax (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Profit After Tax history runs 14 years deep, the most recent figure standing at -$125.4 million for Q1 2026.
- Quarterly Profit After Tax fell 3241.47% year-over-year to -$125.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$415.1 million (down 6736.21% YoY) and the FY2025 annual result came in at -$293.4 million, down 20492.68% from the prior year.
- Profit After Tax was -$125.4 million for Q1 2026 at Minerva Neurosciences, up from -$283.7 million in the prior quarter.
- Across five years, Profit After Tax topped out at $22.5 million in Q3 2024 and bottomed at -$283.7 million in Q4 2025.
- A 5-year average of -$28.2 million and a median of -$7.0 million in 2023 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2024 — Profit After Tax soared 387.88% — and 2025, when it tumbled 6540.09%.
- Minerva Neurosciences' Profit After Tax stood at -$6.7 million in 2022, then plunged by 34.14% to -$9.0 million in 2023, then jumped by 52.65% to -$4.3 million in 2024, then tumbled by 6540.09% to -$283.7 million in 2025, then soared by 55.79% to -$125.4 million in 2026.
- Business Quant data shows NERV's Profit After Tax at -$125.4 million in Q1 2026, -$283.7 million in Q4 2025, and -$2.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | -125.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -125.40 Mn |
| Dec 31, 2025 | -283.67 Mn |
| Sep 30, 2025 | -2.74 Mn |
| Jun 30, 2025 | -3.26 Mn |
| Mar 31, 2025 | -3.75 Mn |
| Dec 31, 2024 | -4.27 Mn |
| Sep 30, 2024 | 22.51 Mn |
| Jun 30, 2024 | -8.23 Mn |
| Mar 31, 2024 | -8.57 Mn |
| Dec 31, 2023 | -9.02 Mn |
| Sep 30, 2023 | -7.82 Mn |
| Jun 30, 2023 | -6.19 Mn |
| Mar 31, 2023 | -6.97 Mn |
| Dec 31, 2022 | -6.73 Mn |
| Sep 30, 2022 | -6.90 Mn |
| Jun 30, 2022 | -8.72 Mn |
| Mar 31, 2022 | -9.76 Mn |
| Dec 31, 2021 | -21.31 Mn |
| Sep 30, 2021 | -9.21 Mn |
| Jun 30, 2021 | -10.59 Mn |